1. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1044,
1996,
Page 2-2
&NA;,
Preview
|
PDF (1117KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
2. |
Hits and misses in treating diabetic complications: part I |
|
Inpharma Weekly,
Volume &NA;,
Issue 1044,
1996,
Page 3-4
Gill Higgins,
Preview
|
PDF (2269KB)
|
|
摘要:
There have been few outright success stories regarding new treatments for diabetic complications over the past few years, but much can be learnt from both the hits and the misses, said Dr David Tomlinson from the University of London, UK, at the 2nd International Conference on ‘Diabetic Complications as Drug Targets’ [London, UK; May 1996]. A number of potential treatments for diabetic complications were reviewed at the meeting, which was organised by William Harvey Research Conferences. In this week's issue,Inpharma® looks at the progress and the pitfalls seen with the aldose reductase inhibitors and glycosylation antagonists. Other agents will be featured next week.
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
3. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1044,
1996,
Page 5-5
&NA;,
Preview
|
PDF (970KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
4. |
Zafirlukast - more days without asthma episodes |
|
Inpharma Weekly,
Volume &NA;,
Issue 1044,
1996,
Page 6-6
&NA;,
Preview
|
PDF (1048KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
5. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1044,
1996,
Page 7-7
&NA;,
Preview
|
PDF (960KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
6. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1044,
1996,
Page 8-8
&NA;,
Preview
|
PDF (1038KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
7. |
Long-awaited clinical data for platelet factors |
|
Inpharma Weekly,
Volume &NA;,
Issue 1044,
1996,
Page 9-10
Larry Prescott,
Preview
|
PDF (2094KB)
|
|
摘要:
The results of 2 separate studies presented at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO) [Philadelphia, Pennsylvania; May 1996] have indicated that newly developed thrombopoietic agents are capable of reducing chemotherapy-induced thrombocytopenia in patients with cancer. The agents involved in the trials were recombinant human thrombopoietin [rhTPO; Genentech; phase I] and pegylated recombinant human megakaryocyte growth and development factor [MGDF; Amgen; phase I/II]. According to the researchers, the addition of these agents to chemotherapy regimens led to a more rapid restoration of platelet levels to baseline and permitted the administration of larger doses of chemotherapy, compared with chemotherapy alone.
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
8. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1044,
1996,
Page 10-10
&NA;,
Preview
|
PDF (1043KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1044,
1996,
Page 11-11
&NA;,
Preview
|
PDF (1084KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|
10. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1044,
1996,
Page 12-12
&NA;,
Preview
|
PDF (1054KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1996
数据来源: ADIS
|